Kelli Bramlett of Thermo Fisher Scientific recently spoke with us at the ASHG annual meeting about microRNA (miRNA) and mRNA interactions in Breast Cancer.
Her poster, titled “Advances in Breast Tumor Biomarker Discovery Methods” explores mRNA and miRNA expressions profiles in breast cancer research samples to potentially identify downstream gene targets that may elicit a disease phenotype.
They used Laser-capture microdissection to collect tumor cells with the ability to spatially locate the cell and its neighboring environment. While traditional RNA sequencing methods require large input amounts, by using the Ion AmpliSeqTM transcriptome workflow they could start with just 10ng of total RNA input. They were able to prepare two different libraries, one to study mRNA and one for miRNA from the same samples; with technical reproducibility. Their research sheds important light into the world of the complex cancer transcriptomes and biomarker discovery.
Leave a Reply